MetaVia AI Stock Analysis
Want to see MTVA full AI Analyst Report?
MetaVia (MTVA) AI Stock Analysis
MetaVia
(NASDAQ:MTVA)
The score is primarily held down by weak financial performance (no revenue, continued losses, and material cash burn with potential dilution risk). Technicals are also modestly negative with the price below key longer-term moving averages and a negative MACD, while valuation metrics offer limited support due to a negative P/E and no dividend yield.
MetaVia (MTVA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.49M
- Dividend Yield
- ―
- Average Volume (3M)
- 114.12K
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 1.41
- Revenue Growth
- ―
- EPS Growth
- 79.26%
- Country
- US
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
MetaVia Business Overview & Revenue Model
Company Description
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational...
MetaVia Financial Statement Overview
Summary
Financials are dominated by early-stage biotech risk: zero revenue, recurring net losses (TTM net income -$14.4M), and substantial ongoing cash burn (TTM operating/FCF about -$15.8M). The key offset is low leverage (minimal debt) and positive equity, but equity has trended down meaningfully, increasing future funding/dilution risk.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -10.00K | -19.00K | -24.00K | -7,000 | -28.00K | -72.00K |
| EBITDA | -14.50M | -12.95M | -27.57M | -12.46M | -11.76M | -15.24M |
| Net Income | -14.45M | -12.97M | -27.59M | -12.47M | -13.97M | -15.28M |
Balance Sheet | ||||||
| Total Assets | 13.27M | 11.12M | 16.26M | 22.78M | 33.53M | 16.80M |
| Cash, Cash Equivalents and Short-Term Investments | 12.63M | 10.28M | 16.02M | 22.43M | 33.36M | 16.39M |
| Total Debt | 177.00K | 210.00K | 136.00K | 203.00K | 0 | 71.00K |
| Total Liabilities | 6.45M | 5.79M | 8.33M | 6.10M | 11.78M | 2.20M |
| Stockholders Equity | 6.82M | 5.33M | 7.93M | 16.68M | 21.75M | 14.60M |
Cash Flow | ||||||
| Free Cash Flow | -15.84M | -15.70M | -24.72M | -10.85M | -11.71M | -15.14M |
| Operating Cash Flow | -15.84M | -15.70M | -24.71M | -10.80M | -11.71M | -15.13M |
| Investing Cash Flow | 0 | -2,000 | -8,000 | -50.00K | 8,000 | -586.00K |
| Financing Cash Flow | 10.88M | 9.96M | 18.30M | -80.00K | 28.68M | 22.03M |
MetaVia Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTVA, the sentiment is Positive. The current price of 1.44 is above the 20-day moving average (MA) of 1.30, below the 50-day MA of 1.48, and below the 200-day MA of 1.61, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 52.98 is Neutral, neither overbought nor oversold. The STOCH value of 65.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MTVA.
MetaVia Risk Analysis
MetaVia disclosed 66 risk factors in its most recent earnings report. MetaVia reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksMetaVia Peers Comparison
Overall Rating
RLYB54Neutral- MTVA45Neutral
CTXR43Neutral
PMN40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| RLYB | 54Neutral | $84.85M | 3.43 | 36.35% | 86.32% | -35.61% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| MTVA | 45Neutral | $9.82M | -0.35 | -209.67% | ― | ― | 79.26% |
| CTXR | 43Neutral | $13.53M | -0.23 | -67.15% | ― | ― | 57.48% |
| PMN | 40Underperform | $35.69M | -0.22 | -143.09% | ― | ― | -169.38% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MTVA | Metavia Inc. | 1.44 | -5.82 | -80.17% | |
| PMN | ProMIS Neurosciences Inc. | 3.76 | -6.00 | -61.46% | |
| CTXR | Citius Pharma | 0.48 | -0.53 | -52.48% | |
| RLYB | Rallybio Corporation | 15.80 | 10.55 | 201.07% | |
| KAPA | Kairos Pharma, Ltd. | 0.51 | -5.03 | -90.81% |
MetaVia Corporate Events
MetaVia Reports Positive Interim Results for DA-1726 Trial
PositiveOn November 5, 2026, MetaVia reported positive interim results from Part 3B of DA-1726’s Phase 1 trial in otherwise healthy adults with obesity. The results, presented on November 4, showed statistically significant 68% placebo-adjusted liver-fat red...
MetaVia highlights DA-1726 obesity trial data progress
PositiveOn October 28, 2026, MetaVia announced that Phase 1 clinical trial data for its investigational dual GLP-1 and glucagon receptor agonist DA-1726 will be presented in an oral session at the Precision Liver Symposium 2026 on November 4 in Denver. The p...
MetaVia Appoints New Chief Medical Officer for Pipeline
PositiveOn October 13, 2026, MetaVia announced that Sarah Kaplan Browne, M.D., had been appointed Chief Medical Officer, effective October 12, 2026, bringing more than two decades of experience in clinical development, regulatory science and clinical medicin...
MetaVia Highlights DA-1726 Preclinical Data for Obesity Program
PositiveOn September 9, 2026, MetaVia reported preclinical tissue distribution data for its obesity drug candidate DA-1726, showing that DA-1726-derived radioactivity is slowly absorbed, broadly distributed, and most concentrated in adipose tissue, with mini...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026